Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic disorder caused by biallelic pathogenic variants in COL7A1, the gene encoding the alpha-1 chain of type VII collagen (C7). While over 100 pathogenic variants in COL7A1 have been linked to RDEB, recurrent variants or hot spots are rare. A recurrent pathogenic variant, c.7485+5G>A (also known as IVS98+5G>A) in intron 98 of COL7A1, has been noted in patients of Hispanic ethnicity seen in the Epidermolysis Bullosa Clinic at Children's Hospital Colorado. We describe the phenotypic characteristics of 17 patients with this variant and compare the phenotypic severity of patients homozygous versus compound heterozygous for the variant. These genotype-phenotype correlations may help to provide prognostic information to patients and families affected by RDEB.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ajmg.a.64032 | DOI Listing |
Dermatol Reports
February 2025
Division of Regenerative and Oncological Dermatological Surgery, Modena University Hospital.
In patients with epidermolysis bullosa (EB), surgery may be required to remove squamous cell carcinoma (SCC) of the hands or to correct pseudo-syndactyly. Dermal substitutes may represent a suitable tool to promote the healing of surgical wounds in EB. We review our experience with a collagen-elastin dermal matrix to promote surgical wound healing due to hand surgery to correct pseudo-syndactyly or SCC resection in patients affected by EB.
View Article and Find Full Text PDFAdv Mater
March 2025
Centre for Craniofacial and Regenerative Biology, King's College London, London, SE1 1UL, UK.
Base editing, a CRISPR-based genome editing technology, enables precise correction of single-nucleotide variants, promising resolutive treatment for monogenic genetic disorders like recessive dystrophic epidermolysis bullosa (RDEB). However, the application of base editors in cell manufacturing is hindered by inconsistent efficiency and high costs, contributed by suboptimal delivery methods. Nanoneedles have emerged as an effective delivery approach, enabling highly efficient, non-perturbing gene therapies both in vitro and in vivo.
View Article and Find Full Text PDFJID Innov
May 2025
Department of Dermatology, Alfred Health, Melbourne, Australia.
Dystrophic epidermolysis bullosa (DEB) is a hereditary skin fragility disease characterized by the loss or dysfunction of collagen VII, predisposing patients to dermal-epidermal separation. This disease is highly associated with the development of progressive fibrosis of the skin and other organs and the occurrence of lethal cutaneous squamous cell carcinomas (cSCCs). These are not only caused by chronic wounding but also by collagen VII deficiency, which may directly alter cellular responses.
View Article and Find Full Text PDFAm J Pathol
March 2025
From the Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland; FICAN West Cancer Research Laboratory, University of Turku and Turku University Hospital, Turku, Finland. Electronic address:
Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer, and the metastatic disease is associated with poor prognosis. Here, the role of complement C5a receptor, C5aR1, was examined in the progression and metastasis of cSCC. C5aR1 expression was increased in cSCC cells in 3D spheroid co-culture model in the presence of fibroblasts, and treatment with recombinant C5a enhanced the invasion of cSCC cells.
View Article and Find Full Text PDFRinsho Ketsueki
March 2025
Department of Hematology, Tokyo Medical and Dental University Hospital.
A 41-year-old woman with myelodysplastic syndrome underwent unrelated bone marrow transplantation following conditioning with fludarabine, busulfan, total body irradiation, and anti-thymocyte globulin. She received tacrolimus and short-term methotrexate for graft-versus-host disease (GVHD) prophylaxis. After engraftment, she developed acute GVHD involving the skin, gut, and liver.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!